March 19, 2026 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the “Investors” page on its website. Q1 2026 Aide Memoire Teva has compiled this document with public information that was
March 19, 2026 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial results on Wednesday, April 29, 2026, at 7:00 a.m. ET. Following
March 19, 2026 09:00 ET | Source: Curia Global, Inc. ALBANY, N.Y., March 19, 2026 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization (CDMO), today announced progress on the expansion at its Glasgow, UK sterile drug product facility as well as enhancements to its proprietary platform for cell line development. The Glasgow, UK,
March 19, 2026 07:00 ET | Source: Tilray Brands, Inc. NEW YORK and SYDNEY, March 19, 2026 (GLOBE NEWSWIRE) — Tilray Medical, a recognized global leader in medical cannabis and a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), today announced its largest portfolio expansion in Australia to date. The expanded medical cannabis offering reinforces
March 19, 2026 04:00 ET | Source: SK pharmteco Inc. RANCHO CORDOVA, Calif., March 19, 2026 (GLOBE NEWSWIRE) — SK pharmteco today announced a significant funding commitment to support strategic initiatives within its viral vector business, while reaffirming its long-term growth strategy across three business units: small molecule, peptides, and viral vectors. SK pharmteco is sharpening its
AIM also intends to pursue Japanese Orphan Drug Designation for Ampligen in treatment of pancreatic cancer March 18, 2026 08:36 ET | Source: AIM ImmunoTech Inc. OCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Japan Patent Office has fully approved a Japanese patent covering the Company’s
Four presentations deliver new insights into zanidatamab, including its differentiated HER2 biology March 18, 2026 07:46 ET | Source: Zymeworks Inc. VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that the
March 18, 2026 05:00 ET | Source: Boehringer Ingelheim Limited World Parasite Awareness Day, held annually on March 20, is an important reminder that parasites such as fleas, ticks and worms are among the most common health threats for pets around the world, yet they can easily be prevented. A global survey among 6,500 pet owners1 shows
March 17, 2026 17:02 ET | Source: Zymeworks Inc. VANCOUVER, British Columbia , March 17, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the acceptance of an oral presentation and six abstracts from its wholly-owned R&D
March 17, 2026 16:35 ET | Source: Adagene Inc. SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that muzastotug will be highlighted in two poster presentations at this year’s AACR Meeting, taking place
New panel expands coverage for Alzheimer’s and Parkinson’s diseases including 15 new biomarkers developed with support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and 12 assays specific to brain and peripheral Tau isoforms | NULISA™ data to be presented in over 11 scientific sessions and 25 posters at the International Conference on
March 17, 2026 09:03 ET | Source: SK pharmteco Inc. RANCHO CORDOVA, Calif., March 17, 2026 (GLOBE NEWSWIRE) — SK pharmteco today announced the successful conclusion of a regulatory inspection of its small molecule North America facility in La Porte, Texas. The U.S. Food and Drug Administration (FDA) carried out a general inspection of the site from February 9
Imprivata Enterprise Access Management now offers facial recognition, AI-powered behavioral analytics, and high-assurance identity verification to further streamline clinical access, improve operational efficiency, and strengthen security posture March 16, 2026 18:00 ET | Source: Imprivata MELBOURNE, March 16, 2026 (GLOBE NEWSWIRE) — Imprivata, a leading provider of access management solutions for healthcare and other mission-critical industries, today introduced
March 13, 2026 09:54 ET | Source: Junshi Biosciences SHANGHAI, March 13, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2025 and provided corporate updates. FINANCIAL
UK marks first international launch of the HYDROS Robotic System, with additional international expansion planned in 2026 March 12, 2026 09:00 ET | Source: PROCEPT BioRobotics SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) — PROCEPT BioRobotics (Nasdaq: PRCT), today announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform for delivering Aquablation therapy
